Project Grant CLSS00000066506

The federal Project Grant award with ID DP2DA062283 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,542,500 grant, awarded on September 1, 2024, will support the development of novel econometric methods and a unified framework for integrating real-world evidence (RWE) to analyze inconclusive randomized controlled trials (RCTs) focused on opioid use disorder (OUD) treatments. The project, to be conducted by Weill...

The National Institute on Drug Abuse (NIDA) awarded a $220,668 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Amalgent Therapeutics, Inc. in Greenville, NC. This grant supports the development of a novel opioid adjuvant technology that aims to enhance the pain-relieving efficacy of opioid medications while mitigating risks such as abuse potential, tolerance, and neuropathic pain. The project has two key objectives: 1) investigating the mechanism by which the...

The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $267,000 Project Grant (R21DA058120) to The Children's Hospital Corporation (Boston Children's Hospital) to develop depot formulations for on-demand, tamper- and diversion-proof delivery of opioids. The goal is to create injectable polymer-based depot formulations that are covalently bonded to opioids via photolabile linkers, which would make the formulations resistant to...

The Louisiana Department of Health (LDH), through its Office of Behavioral Health (OBH) Division, has been awarded a $54,004,380 Project Grant by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Opioid STR Federal Grant Program (CFDA 93.788). The Louisiana State Opioid Response (LASOR) 4.0 program will enhance existing statewide prevention, treatment, and recovery support services for individuals with or at risk for opioid use disorder (OUD) and/or stimulant use...

The Doya Natsu Healing Center (DNHC) of the Eastern Shoshone Tribe was awarded a $591,268 Project Grant under the Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) program administered by the Substance Abuse and Mental Health Services Administration (SAMHSA). The grant will fund a 5-year Tribal Opioid Response (TOR4) project to increase access to culturally-driven, evidence-based services for treating opioid use disorder (OUD) and substance...

This Project Grant award, funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Substance Abuse and Mental Health Services Projects of Regional and National Significance program (CFDA 93.243), provides $182,536 to the Confederated Tribes of Grand Ronde in Oregon. The goal of the project is to decrease opioid use and prevent fatal and non-fatal opioid overdoses within the tribal community by implementing evidence-based programs, medication-assisted treatment...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is intended to investigate whether a pharmacist-integrated model of opioid use disorder (OUD) treatment can increase naloxone co-prescribing in primary care. The $193,336 award to Trustees of Dartmouth College will fund a research project with three aims: (1) describing federal, state, and clinic-level policies and OUD interventions impacting...

This federal Project Grant award of $4,665,000 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington. The award will fund the development and testing of a novel "Community-Based Opioid Treatment (CBOT)" implementation strategy to deliver buprenorphine for opioid use disorder treatment and HIV prevention/care services to people who use opioids. The project will involve two parts -...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $598,312 to Addinex Technologies, Inc. to integrate and assess the practicality of a closed-loop medication management system for opioid pain management targeting ambulatory patients with extremity fractures being discharged from the emergency department. The key objectives are to adapt the Addinex system to seamlessly integrate with hospital...

This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...